Archives
-
ASB5 in Muscle Satellite Cells: Marker, Not Driver
2026-10-05
The reference study identifies ASB5 as an abundant and specific marker of mouse muscle satellite cells and myogenic progenitors, then tests whether the gene is required for muscle development or regeneration. Loss of Asb5 did not produce major developmental, regenerative, or ex vivo satellite-cell defects, separating marker utility from functional necessity while revealing a reduction in skeletal-muscle Tnfa expression.
-
How P. gingivalis May Worsen COPD
2026-10-05
A 2026 study links periodontitis-associated Porphyromonas gingivalis with aggravated COPD-like lung disease through pulmonary pathogen relocation, epithelial chemokine production, and damaging neutrophil activity. Its value lies in connecting oral microbial disease with a defined lung inflammatory circuit, while its mouse-model evidence remains subject to important translational limits.
-
VE-822 and ATR Inhibition in Radiosensitizer Research
2026-10-04
VE-822 is a research compound described as a selective ATR inhibitor, but the supplied 2025 comparative study evaluated the related ATR inhibitor M6620 rather than VE-822 itself. This overview separates direct evidence from target-class interpretation, examining radiosensitization, 2D versus 3D models, pancreatic cancer relevance, and key translational limitations.
-
SB203580 in p38 MAPK Research: Evidence and Limits
2026-10-03
SB203580 is a pyridinyl imidazole compound used to interrogate p38 MAPK signaling, but its biochemical potency should not be treated as proof of pathway-specific action in cells or disease models. This overview separates supplier-reported activity from peer-reviewed findings, places recent trigeminal ganglion research in context, and explains how pharmacological evidence can be compared with genetic and mechanistic approaches. Particular attention is given to off-target considerations, model limitations, and the boundaries of translating inflammatory pain findings to broader neuroprotection or therapeutic claims.
-
SB203580: p38 MAPK Assay Workflows
2026-10-02
Build more decisive p38 MAPK experiments with SB203580, from solvent preparation and concentration selection to pathway-specific validation. The workflow also translates recent trigeminal ganglion findings into practical assays for inflammatory signaling, neuroprotection studies, and mechanistic cross-checks.
-
LY2109761: Translating TGF-β Pathway Control
2026-10-01
LY2109761 offers a receptor-proximal way to interrogate TGF-β biology across tumor progression, cellular plasticity, radiosensitization, and fibrosis. This thought-leadership guide connects dual TβRI/II kinase inhibition with biomarker strategy, model selection, experimental rigor, and translational decision-making.
-
Cre mRNA: Recombination Meets Tissue Delivery
2026-10-01
A translational perspective on how transient Cre recombinase mRNA, m1Ψ chemistry, Cap 1 architecture, and emerging tissue-targeted lipid nanoparticles can be integrated into more precise gene-editing workflows.
-
Purifying HLA-G+ Extravillous Trophoblasts
2026-09-30
Tsuda and colleagues present a reproducible workflow for isolating viable, highly pure HLA-G+ extravillous trophoblasts from human placental tissue and evaluating their phenotype and interactions with maternal immune cells. The approach addresses major limitations of animal models, trophoblast lines, stem-cell systems, and organoids by preserving clinically relevant human MHC and immune-tolerance features for short-term functional studies.
-
Predicting Netarsudil–siRNA Nanoparticle Codelivery
2026-09-30
Slaughter and colleagues developed a quantitative workflow for predicting whether ionizable drugs can complex siRNA and support nanoparticle encapsulation. Netarsudil emerged as a high-performing candidate, enabling experimental codelivery of CTGF-targeting siRNA in fibrotic human trabecular meshwork cells and linking formulation descriptors with changes in gene expression and actin organization.
-
β-Sitosterol, TBX20, and Colorectal Cancer
2026-09-29
A 2025 study identifies β-sitosterol as an anti-tumour component of Herba Sarcandrae and connects its activity to stabilization of the tumour-suppressive transcription factor TBX20. Network pharmacology, colorectal cancer cell assays, chemotherapy-sensitivity experiments, and xenograft studies together support a mechanism involving reduced proliferation, increased apoptosis, and inhibition of ubiquitin-mediated TBX20 degradation.
-
Disulfiram: From Proteasomes to Pyroptosis
2026-09-29
Disulfiram is evolving from a clinically familiar anti-alcoholism drug and dopamine β-hydroxylase inhibitor into a strategically useful probe of proteasome function, apoptotic cancer cell death, and GSDMD-linked pyroptosis. This thought-leadership analysis connects mechanistic evidence with practical study design for translational cancer and inflammation researchers.
-
Metoprolol for Disease-Aware Research Workflows
2026-09-28
Metoprolol enables receptor-focused experiments spanning cardiovascular signaling, inflammation, and exploratory oncology assays. This guide combines practical beta1-blockade workflows with disease-aware pharmacokinetic and tissue-distribution principles from recent MASH research.
-
Firefly Luciferase mRNA: Delivery Assay Workflows
2026-09-28
Use Firefly Luciferase mRNA (ARCA, 5-moUTP) to compare transfection, expression, and delivery conditions with a sensitive light-producing readout. This practical guide also explains how to test freeze–thaw effects on lipid nanoparticle delivery without confusing the reporter assay with the formulation method.
-
ASB5 Marks Muscle Satellite Cells but Is Dispensable
2026-09-27
The study identifies ASB5 as a highly expressed marker of muscle satellite cells and their progeny, then tests its function using a CRISPR-Cas9 knockout mouse model. Despite its useful marker profile, Asb5 loss did not measurably impair muscle growth, satellite-cell behavior in myofiber explants, or regeneration after acute injury under the conditions examined.
-
Prochlorperazine-Associated Neuroleptic Malignant Syndrome
2026-09-26
This case report describes neuroleptic malignant syndrome (NMS) in a 76-year-old man after two weeks of standard-dose prochlorperazine, emphasizing that a compelling clinical pattern can occur without marked creatine phosphokinase elevation or other typical laboratory abnormalities. The case highlights medication-history review, exclusion of competing diagnoses, and prompt supportive pharmacotherapy; it does not establish comparative treatment efficacy or a general risk estimate.